Kepos Capital’s Pfizer PFE Stock Holding History

Kepos Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-150,000	Closed	-$4.16M	–	249
2024 Q1	$4.16M	Buy	150,000 +50,000	+50%	+$1.39M	1.07%	30
2023 Q4	$2.88M	Buy	+100,000	New	+$3.02M	0.93%	32
2020 Q3	–	Sell	-105,400	Closed	-$3.27M	–	288
2020 Q2	$3.27M	Buy	+105,400	New	+$3.58M	0.42%	75
2019 Q4	–	Sell	-29,457	Closed	-$1M	–	407
2019 Q3	$1M	Buy	+29,457	New	+$1.07M	0.1%	114
2019 Q2	–	Sell	-153,531	Closed	-$6.19M	–	385
2019 Q1	$6.19M	Sell	153,531 -8,050	-5%	-$322K	0.46%	51
2018 Q4	$6.69M	Buy	161,581 +83,581	+107%	+$3.47M	0.52%	31
2018 Q3	$3.26M	Sell	78,000 -95,927	-55%	-$3.69M	0.17%	126
2018 Q2	$5.99M	Buy	173,927 +28,949	+20%	+$989K	0.31%	71
2018 Q1	$4.88M	Buy	144,978 +8,338	+6%	+$287K	0.29%	74
2017 Q4	$4.7M	Buy	+136,640	New	+$4.66M	0.42%	44

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Kepos Capital's PFE Position: Q2 2024 in Review

Kepos Capital sold out of Pfizer (PFE) in Q2 2024, closing a stake of 150,000 shares — an estimated $4.16M sold.

Kepos Capital first reported a position in PFE in Q4 2017 and held it in 10 quarters. The position peaked at $6.69M in Q4 2018. 2,873 funds tracked by Wall St. Rank hold PFE as of Q2 2024.

Kepos Capital reported no remaining Pfizer position as of Q2 2024 after selling out during the quarter.
Kepos Capital sold 150,000 Pfizer shares in Q2 2024, an estimated $4.16M.
Kepos Capital first reported a position in Pfizer in Q4 2017 and held it in 10 quarters.
Kepos Capital's Pfizer position peaked at $6.69M in Q4 2018.
2,873 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.

Based on Kepos Capital's 13F filing for Q2 2024, filed 13 Aug 2024.